肠道菌群
代谢组学
生物
微生物学
遗传学
细菌
代谢组
计算生物学
DNA测序
肠道微生物群
生物信息学
作者
Qingxian Chen,Lixia Liu,Cuilan Zhang,Peiqiong Su,Dingfu Li,Yu Zheng,Qingqing Chen
标识
DOI:10.1016/j.fct.2026.116180
摘要
Currently, sulfonylureas, a class of medications used in type 2 diabetes mellitus (T2DM) treatment, are widely applied, but the problem of secondary failure isn't fully understood. This study aims to explore the potential mechanisms of secondary failure of sulfonylureas (SFS) and to identify reliable predictive biomarkers. In this study, 16S rDNA sequencing technology and non-targeted metabolomics were used to analyze the differences in gut microbiota and metabolic products between the SFS and sulfonylurea effective (SE) groups. The results of 16S rDNA sequencing indicated that there are differences in composition between two groups. Seventeen different bacterial types were identified, including six types from SFS patients and eleven from SE. SFS might be linked to disturbances in energy metabolism, amino acid metabolism, nucleotide metabolism, and lipid metabolism within the gut microbiota. Metabolomics results showed 66 different metabolites between two groups (49 metabolites were upregulated, and 17 metabolites were downregulated). Correlation analysis between gut bacteria and fecal metabolites revealed that 4 types of gut bacteria were significantly linked to 5 types of metabolites. This study reveals distinct gut microbiota composition in patients with sulfonylurea secondary failure, helping us understand changes in gut metabolites and providing new biomarkers for personalized treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI